CLINICAL TRIAL / NCT04687215
Diabetic Neuropathy in Spinal Cord Stimulator Patients
- Observational
- Recruiting
- NCT04687215
Contact Information
- Edward Fox
Spinal Cord Stimulation Improves Pain, Arterial Stiffness and Vascular Flow in Lower Extremities in Patients With Diabetes Mellitus Type II A Multidisciplinary Collaborative Prospective Study
The objective of this study is to assess the effect Spinal Cord Stimulators have toward improving vascular changes of diabetes mellitus in patients eligible for SCS placement based on their condition of painful diabetic neuropathy; we will evaluate improving their disability and quality of life, improving micro-circulatory changes induced by Diabetes Mellitus (DM), improving macro-circulatory changes induced by DM and improving arterial stiffness of the vessels of the lower extremity.
This is a single-center, pilot study to investigate a preventative modality, spinal cord
neuromodulation, that would contribute to reversing the physiologic changes that occur in
the lower extremities of diabetic patients. Patients who have been diagnosed with DM type
II for at least 1 year and refractory painful diabetic peripheral neuropathy of the lower
extremities who are scheduled to receive a spinal cord stimulator may be enrolled in this
study pending eligibly for all other criteria.
Once eligibility and consent have been confirmed, each subject will go through a baseline
visit where data will collected through a series of questionnaires, a clinical and
psychological evaluation by a licensed professional. Subjects will be asked to come back
for a series of vascular test prior to their device implantation. This vascular testing
will be done at the vascular lab at the University of Chicago Medical Center by trained
vascular physicians and techs.
Prior to any study related procedures, all subjects must first sign the approved ICF.
This will be performed by the PI or an approved member of the study staff who has been
delegated by the PI do so and in a private setting with ample time given to the subject
to review and ask any questions regarding the study. Once the ICF has been signed, a copy
will be given to the subject and the original will be placed in their research or medical
chart.
Background Data
Once the ICF has been complete, demographic data such as name, age, gender will be
collected. Along with demographic information, we will collect medical, surgical and
medication history for each subject at the initial baseline visit.
Vascular Testing
Before the Spinal Cord Stimulator procedure, all patients enrolled in the study will
undergo baseline vascular testing. The following test will be performed on each subject.
Subjects will only go through this portion of the study if they receive pre-certification
by their insurance for their SCS procedure. Below is a list of tests that will be
performed:
1. Flow mediated arterial dilation and by measuring pedal and digital level waveforms
and pressure.
2. Doppler flowmetry (Laser Doppler flowmetry if available) by Duplex Scan of lower
extremities
3. Ankle Brachial Index
4. Pulse Pressure and aortic pulse wave velocity
5. Peripheral vascular compliance of the lower extremity
SCS Procedure
The SCS procedure is being done as part of the subject's clinical care. The subject
would be receiving this procedure, even if they do not agree to participate in this
study. All patients will have 2 temporary SCS trial leads placed transcutaneously
and tunneled to limit the risk for infection. At the end of the trial interval,
patients will repeat the vascular testing at 2 weeks post-op at the time just prior
to device removal, as well as complete the clinical evaluations as above.
The SCS waveform used will be consistent and similar for all patients enrolled; at 1
week, study will allow minor SCS waveform modifications to recapture stimulation,
but waveforms will be maintained within established parameters in accordance with
device used. All patients will attempt to complete the 2 weeks trial; early removal
will be performed for the following situations: intolerable pain with stimulation
(increase pain >4 points from baseline), infection, neurological deficit (sensory of
motor), patient request. Leads will be pulled 2 weeks after placement and patients
will be seen 1 week after the leads are pulled. At that time, patient will exit the
study and can choose definitive implantation if satisfied with the trial results.
Study Questionnaires and Assessments
At various time intervals, all subjects will be asked to complete a series of
questionnaires and assessments. These questionnaires are intended to evaluate their
quality of life, pain levels, patient satisfaction, functional capacities and mental
health. All questionnaires are validated and have been chosen for a specific study
endpoint. Below is the list of questionnaires and a brief description of each one.
For more specific details on when each will be administered, please refer to the
schedule of events (Appendix A).
List of Questionnaires
- Numerical Rating Scale (NRS)
- Assessment for rating pain on a numerical scale
- Michigan Diabetic Neuropathy Score (MDNS) o Assessment used to assess the
degree of diabetic neuropathy
- Patient Global Impression of Change (PGIC)
o Used to assess subject satisfaction
- Oswestry Disability Index (ODI)
o Used to assess a subject's functional capacity
- Health Related Quality of Life (H-RQol)
o Assesses physical and mental health over time
- Short Form McGill Pain Questionnaire (SF-MPQ)
o Assesses both the subject's intensity and quality of pain
- Medication Quantification Scale III (MQS-III) o Used to quantify medication
regimen
Study Visits
This study consists of 5 total clinic visits. Subjects will be asked to come back
prior to their temporary SCS placement for a series of vascular testing. If the
subject's insurance does not pre-certify them for the trial SCS procedure, the
vascular testing will not be completed and they will be withdrawn from the study.
For specific detail in what each visit entails, please refer to the study SCHEMA.
Below are the list of visits and when they occur.
a. Visit 1 (Baseline) b. Visit 2 (Vascular Testing) c. Visit 3 (1 Week-Post Procedure
Visit) d. Visit 4 (2 Weeks-Post Procedure Visit) e. Visit 5 (1 Week Post-Lead Pull Visit)
Gender
All
Age Group
18 Years and up
Accepting Healthy Volunteers
No
Inclusion Criteria:
1. Patients with DM type 2 of more than 1-year duration
2. DM stage 3 or less
3. Patients ≥18 years of age
4. Refractory painful diabetic peripheral neuropathy of the lower extremities
5. ABI index <0.9
Exclusion Criteria:
1. Patients on anticoagulants
2. Patients with active infections
3. Patients with HbA1>10
4. Psychiatric disorders and cognitive dysfunctions
5. Illicit Drug Usage
6. Patients on dialysis
7. BMI>35.0
8. Surgery within the last 30 days
9. Ulcer of the lower extremities
10. Calcification of the peripheral arteries